Secondary amyloidosis epidemiology and demographics: Difference between revisions
No edit summary |
|||
Line 8: | Line 8: | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Incidence=== | ===Incidence=== | ||
*The [[incidence]] of amyloidosis is approximately | *The [[incidence]] of AA amyloidosis is approximately 0.16 per 100,000 individuals in 2008 in the United kingdom.<ref name="pmid28686088">{{cite journal |vauthors=Lane T, Pinney JH, Gilbertson JA, Hutt DF, Rowczenio DM, Mahmood S, Sachchithanantham S, Fontana M, Youngstein T, Quarta CC, Wechalekar AD, Gillmore JD, Hawkins PN, Lachmann HJ |title=Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre |journal=Amyloid |volume=24 |issue=3 |pages=162–166 |date=September 2017 |pmid=28686088 |doi=10.1080/13506129.2017.1342235 |url=}}</ref> | ||
===Prevalence=== | ===Prevalence=== | ||
* The [[prevalence]] of AA amyloidosis is 5,000 to 10,000 per 100,000 individuals with chronic [[inflammatory]] process per year worldwide.<ref name="KoivuniemiPaimela2009">{{cite journal|last1=Koivuniemi|first1=Riitta|last2=Paimela|first2=Leena|last3=Suomalainen|first3=Risto|last4=Törnroth|first4=Tom|last5=Leirisalo-Repo|first5=Marjatta|title=Amyloidosis is frequently undetected in patients with rheumatoid arthritis|journal=Amyloid|volume=15|issue=4|year=2009|pages=262–268|issn=1350-6129|doi=10.1080/13506120802524676}}</ref> | |||
===Mortality rate=== | ===Mortality rate=== | ||
*The [[mortality rate]] of systemic amyloidosis is approximately 100 per 100,000 deaths in developed countries.<ref name="pmid16409147">{{cite journal |vauthors=Pepys MB |title=Amyloidosis |journal=Annu. Rev. Med. |volume=57 |issue= |pages=223–41 |date=2006 |pmid=16409147 |doi=10.1146/annurev.med.57.121304.131243 |url=}}</ref> | * The [[mortality rate]] of systemic amyloidosis is approximately 100 per 100,000 deaths in developed countries.<ref name="pmid16409147">{{cite journal |vauthors=Pepys MB |title=Amyloidosis |journal=Annu. Rev. Med. |volume=57 |issue= |pages=223–41 |date=2006 |pmid=16409147 |doi=10.1146/annurev.med.57.121304.131243 |url=}}</ref> | ||
===Age=== | ===Age=== | ||
* | * Secondary amyloidosis more commonly affects children.<ref name="BilginerAkpolat2011">{{cite journal|last1=Bilginer|first1=Yelda|last2=Akpolat|first2=Tekin|last3=Ozen|first3=Seza|title=Renal amyloidosis in children|journal=Pediatric Nephrology|volume=26|issue=8|year=2011|pages=1215–1227|issn=0931-041X|doi=10.1007/s00467-011-1797-x}}</ref> | ||
===Race=== | ===Race=== | ||
* There is no racial predilection to secondary amyloidosis. | |||
===Gender=== | ===Gender=== | ||
*Men are more commonly affected by amyloidosis than women.<ref name="pmid21494083">{{cite journal |vauthors=Shin YM |title=Hepatic amyloidosis |journal=Korean J Hepatol |volume=17 |issue=1 |pages=80–3 |date=March 2011 |pmid=21494083 |pmc=3304630 |doi=10.3350/kjhep.2011.17.1.80 |url=}}</ref> | * Men are more commonly affected by amyloidosis than women.<ref name="pmid21494083">{{cite journal |vauthors=Shin YM |title=Hepatic amyloidosis |journal=Korean J Hepatol |volume=17 |issue=1 |pages=80–3 |date=March 2011 |pmid=21494083 |pmc=3304630 |doi=10.3350/kjhep.2011.17.1.80 |url=}}</ref> | ||
==References== | ==References== |
Revision as of 20:57, 30 October 2019
Secondary amyloidosis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Secondary amyloidosis epidemiology and demographics On the Web |
American Roentgen Ray Society Images of Secondary amyloidosis epidemiology and demographics |
Secondary amyloidosis epidemiology and demographics in the news |
Blogs on Secondary amyloidosis epidemiology and demographics |
Risk calculators and risk factors for Secondary amyloidosis epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]
Overview
The incidence of amyloidosis is approximately 1.2 per 100,000 individuals per year worldwide. The mortality rate of systemic amyloidosis is approximately 100 per 100,000 deaths in developed countries. In amyloidosis, the mean age of presentation is 55 - 60 years. Men are more commonly affected by amyloidosis than women.
Epidemiology and Demographics
Incidence
- The incidence of AA amyloidosis is approximately 0.16 per 100,000 individuals in 2008 in the United kingdom.[1]
Prevalence
- The prevalence of AA amyloidosis is 5,000 to 10,000 per 100,000 individuals with chronic inflammatory process per year worldwide.[2]
Mortality rate
- The mortality rate of systemic amyloidosis is approximately 100 per 100,000 deaths in developed countries.[3]
Age
- Secondary amyloidosis more commonly affects children.[4]
Race
- There is no racial predilection to secondary amyloidosis.
Gender
- Men are more commonly affected by amyloidosis than women.[5]
References
- ↑ Lane T, Pinney JH, Gilbertson JA, Hutt DF, Rowczenio DM, Mahmood S, Sachchithanantham S, Fontana M, Youngstein T, Quarta CC, Wechalekar AD, Gillmore JD, Hawkins PN, Lachmann HJ (September 2017). "Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre". Amyloid. 24 (3): 162–166. doi:10.1080/13506129.2017.1342235. PMID 28686088.
- ↑ Koivuniemi, Riitta; Paimela, Leena; Suomalainen, Risto; Törnroth, Tom; Leirisalo-Repo, Marjatta (2009). "Amyloidosis is frequently undetected in patients with rheumatoid arthritis". Amyloid. 15 (4): 262–268. doi:10.1080/13506120802524676. ISSN 1350-6129.
- ↑ Pepys MB (2006). "Amyloidosis". Annu. Rev. Med. 57: 223–41. doi:10.1146/annurev.med.57.121304.131243. PMID 16409147.
- ↑ Bilginer, Yelda; Akpolat, Tekin; Ozen, Seza (2011). "Renal amyloidosis in children". Pediatric Nephrology. 26 (8): 1215–1227. doi:10.1007/s00467-011-1797-x. ISSN 0931-041X.
- ↑ Shin YM (March 2011). "Hepatic amyloidosis". Korean J Hepatol. 17 (1): 80–3. doi:10.3350/kjhep.2011.17.1.80. PMC 3304630. PMID 21494083.